US20080026007A1 - Potentiation of the immune response - Google Patents

Potentiation of the immune response Download PDF

Info

Publication number
US20080026007A1
US20080026007A1 US11/703,058 US70305807A US2008026007A1 US 20080026007 A1 US20080026007 A1 US 20080026007A1 US 70305807 A US70305807 A US 70305807A US 2008026007 A1 US2008026007 A1 US 2008026007A1
Authority
US
United States
Prior art keywords
infection
peptide antigen
cells
boropro
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/703,058
Inventor
Brigitte Huber
Tracy Schmitz
Robert Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/703,058 priority Critical patent/US20080026007A1/en
Publication of US20080026007A1 publication Critical patent/US20080026007A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to treatment of viral infections using organic compounds which interact with T-cell enzymes.
  • CD4 + T-cells are a key component of the immune system. Attempts have been made to increase the CD4 + counts of AIDS patients, and some of these efforts, notably treatment with protease inhibitors, have met with considerable success. Other approaches, e.g., stimulation of the immune response by vaccination with viral peptides, have been less successful. The reasons for CD4 + depletion in AIDS, and resistance of CD4 + cells to stimulation by some therapies are not fully understood.
  • the activation state of human T-cells can be affected by compounds which interact with a cytoplasmic post-prolyl dipeptidase activity which has similarities to, but is distinct from, the membrane-bound T-cell serine protease CD26.
  • the compounds useful in the invention are inhibitors of this activity, which is, in naturally-occurring T-cells in healthy individuals, involved in protection of T-cells from apoptosis, or programmed cell death. Thus, in high concentrations, the inhibitors hasten the death of T-cells, by inhibiting the protective enzyme.
  • the inhibitors exhibit a paradoxical effect: they are potent stimulators of T-cell activity in HIV-infected individuals.
  • the concentrations of inhibitor which induce this T-cell stimulatory response at very low (on the order of 10 ⁇ 8 -10 ⁇ 12 M), and therefore the inhibitors can be used with minimal side effects, even if, in larger doses, the inhibitors would be toxic.
  • the invention features a method for stimulating proliferation of T-cells of a human patient suffering from a disease state characterized by the inability of the patients' T-cells to respond normally to T-cell proliferation-inducing stimuli; the method involves contacting the T-cells with an organic compound at a concentration below 10 ⁇ 8 M, wherein the compound is characterized in that it binds to the post-prolyl cleaving dipeptidase activity present in the cytoplasm of human T-cells, e.g., CD4 + cells or Jurkat cells.
  • Treatment according to the invention can be in vitro or in vivo.
  • the enzyme-interacting compound of the invention is administered such that the blood concentration in the patient (e.g., an HIV-infected patient) is below 10 ⁇ 11 .
  • the compounds can also be used in vitro at low concentrations to stimulate proliferation of non-infected, beneficial T-cells, such as CD4 + cells and CTL's.
  • PBMC are isolated from a patient and incubated with a concentration of lower than 10 ⁇ 8 M of the compound, to bring about proliferation of T-cells, which are then reinfased into the patient.
  • T-cell cytoplasmic enzyme which is a multimeric (i.e., multiple subunit) enzyme, exhibits an increased affinity of the enzyme for its natural substrate or ligands, allowing the previously blocked T-cell to proceed to full activation, and hence survival, proliferation, and interleukin-2 production.
  • Stimulation of the T-cell immune response in HIV-infected patients according to the invention yields increased numbers of immune effector cells, which can fight both HP, itself and other opportunistic pathogens.
  • Treatment according to the invention has the advantages of specificity and low toxicity, not just because of the low concentrations of inhibitor which can be used, but also because, in T-cells of patients not infected with a virus such as HIV, the inhibitors have no discernable effect. Furthermore, treatment according to the invention advantageously does not necessarily require in vitro manipulation of the T-cells from HIV-infected patients. Furthermore, no immunization is required, and treatment will be effective even where HIV proteins have mutated because the therapy targets a cellular enzyme. The fact that, in T-cells treated according to the invention in vitro, no increase in the level of the HIV protein p24 is observed, probably indicates that the T-cells which are infected with HIV are not stimulated by the low dose inhibitor treatment of the invention.
  • the invention also permits immunization of HIV-infected patients with, e.g., HIV peptides. Under normal circumstances, such patients cannot be vaccinated because of the defect in the T-cell stimulation pathway.
  • Use of inhibitors in low doses as adjuvants can render T-cells responsive to vaccination with HIV antigens, in particular peptides.
  • Treatment of HIV-infected patients with low doses of inhibitors according to the invention can also enhance the activity of other AIDS drugs, in particular protease inhibitors.
  • treatment according to the invention generally fails to bring about an increase in CD4 ⁇ count in patients whose CD4 ⁇ count is already very low, i.e., below about 400.
  • the CD4 ⁇ count can be increased to above this level using known protease inhibitors, and the newly generated CD4 ⁇ T-cells resulting from such treatment are particularly susceptible to the stimulatory effects of treatment according to the invention, leading to an optimal combination AIDS therapy.
  • the drugs are administered orally.
  • inhibitors of the invention can also be used to produce an adjuvant effect in HIV-negative individuals, who are to be immunized with peptides or other viral antigens; this mode of vaccination can be used for prophylaxis for HIV, as well as any other viral pathogen.
  • CTL cytolytic T-lymphocyte
  • the invention should make it possible to produce significant CTL responses to viral peptides, e.g., peptides from influenza, HIV, human papilloma virus, and herpes peptides.
  • This adjuvant effect can also be used to stimulate CTL responses to peptide antigens from other pathogens as well, e.g., pathogenic bacteria such as toxigenic E. coli , and protozoan pathogens such as the pathogens which are the causative agents of malaria and amoebic dysentery.
  • pathogenic bacteria such as toxigenic E. coli
  • protozoan pathogens such as the pathogens which are the causative agents of malaria and amoebic dysentery.
  • the compounds, when used as adjuvants are preferably administered orally.
  • the invention provides a new and highly advantageous method of potentiating the immune response in both HIV infected and uninfected patients, in methods employing extremely low concentrations of inhibitors which, at these concentrations, exhibit a paradoxical effect (i.e., they act as stimulatory rather than inhibitory molecules, as they would at higher concentrations).
  • the very low concentrations employed according to the invention allows treatment with minimal side reactions and toxicity.
  • the specificity of the treatment of the invention also avoids such adverse effects, which are seen, for example, in treatment with immune stimulatory compounds such as interleukin-2.
  • FIG. 1 is a pair of graphs showing the lymphocyte stimulatory effect of treatment of the invention on peripheral blood mononuclear cells (PBMC) from HIV-infected and uninfected patients.
  • PBMC peripheral blood mononuclear cells
  • FIG. 2 is a graph illustrating the T-cell stimulatory effects of two inhibitory compounds used according to the invention.
  • FIGS. 3, 4 , and 9 are graphs showing stimulatory effects of treatment according to the invention in lymphocytes of HIV-infected patients, compared to treatment using two control compounds.
  • FIG. 5 is a graph illustrating a stimulatory effect of an inhibitor according to the invention on PBMC in vitro, showing the correlation with CD4 + counts.
  • the data are plotted as the natural 10 g of the stimulation index (vertical dimension) versus the natural log of the CD4 ⁇ count of the patient (horizontal dimension).
  • FIG. 6 is a histogram demonstrating that an inhibitor according to the invention induces dose-dependent apoptosis in resting T-cells (these dosages are higher than the extremely low doses used according to the invention).
  • FIG. 7 is a histogram demonstrating that an inhibitor according to the invention induces, at higher doses than in the invention, dose-dependent apoptosis in both CD26 + and CD26 + populations of PBMC.
  • FIG. 8 is a graph showing that an inhibitor of CD26 inhibited the cytoplasmic enzyme as well.
  • Any organic compound can be used according to the invention which exhibits the following properties: (1) it is capable of crossing the membrane of human T-cells to reach the cytoplasm, where the compound can (2) intereact with the cytoplasmic dipeptidase present in the T-cells, in order to (3) stimulate activation/proliferation of T-cells (and most preferably CD4 + cells or CTL's) at concentrations below 10 ⁇ 8 M.
  • the first step is to provide a cytoplasmic enzyme preparation.
  • the preparation need not be a pure enzyme sample; a crude cytoplasmic extract is sufficient to screw compounds for the desired activity.
  • the extract can be prepared from any human T-cell line which is negative for CD26; an example of such a suitable cell line is the commercially available Jurkat cell line.
  • a suitable enzyme-containing cell extract can be prepared as follows. First, Jurkat cells (10 6 -10 11 cells) are grown and a cell pellet is obtained by centrifugation. The cell pellet is stored in frozen condition.
  • the frozen pellet is thawed by the addition of ice cold lysis buffer, in the amount of approximately 1 ml per 10 8 cells.
  • the liquified material is homogenized with ten strokes of a Dounce homogenizer, and then clarified by centrifugation at 1500 g.
  • the supernatant is removed (and saved), and the 1500 g. pellet is resuspended in lysis buffer and homogenized with ten strokes of a Dounce homogenizer. Clarification is again carried out by centrifugation at 1500 g, 4° C.
  • the 1500 g supernatants are then combined, and EDTA is added to 5 mM.
  • the resultant liquid is centrifuged at 75,000 g at 4° C. for twenty minutes, and the supernatant is then removed and centrifuged at 175,000 g. at 4° C., for 60 minutes.
  • the resultant supernatant, containing the cytosolic extract is the DPPV activity-containing preparation used in the assay, described below, for candidate therapeutic compounds of the invention.
  • the assay is based on our observation that the T-cell cytoplasmic enzyme of interest is a post-prolyl cleaving serine protease. We therefore chose as a reporter substrate a compound which contains proline in the penultimate position; any of a number of substrates meeting this requirement can be used.
  • a fluorescent cleavage assay using the substrate AlaProAFC.
  • a colorimetric assay can be carried out using as a substrate Gly-Pro-pNA.
  • the choice of terminal amino acid is not critical, provided that the substrate contain a fire: terminal amino group.
  • test samples multiple samples are run containing varying concentrations, down to 10 ⁇ 8 M, of the test compound.
  • the sample (with or without test compound) is placed in a cuvette, and inserted into a fluoresent spectrometer. Enzymatic activity is measured as the accumulation of fluoresence intensity (i.e., substrate cleavage product) over time (1 min.).
  • fluoresence intensity i.e., substrate cleavage product
  • a compound is identified as an inhibitor if the accumulative fluoresence is decreased as a result of the presence of the inhibiting compound.
  • in vitro assays can be carried out using candidate compounds of the invention, prior to their use in vivo.
  • One such assay employs the candidate compound at a very low concentration, in a test designed to determine whether at low concentrations the compound can stimulate the proliferation of PBMC from HIV infected patients in vitro. As is shown in the data of FIG. 4 , stimulation can be measured by, e.g., incorporation of a labelled nucleotide.
  • the compounds can also be tested at higher doses to determine whether they exhibit the opposite effect of proliferation, as above, i.e., dose-dependent apoptosis caused by enzyme inhibition, as in the experiments of FIG. 6 .
  • compounds which are potentially capable of apoptosis induction at high doses and proliferation induction at low doses are those which, at normal or high doses, inhibit cytoplasmic T-cell dipeptidase, and can cross the T-cell membrane into the T-cell cytoplasm, where the enzyme interaction occurs.
  • the compounds thus should be organic compounds which have a free amino group at the amino terminus; a proline or proline analog at the penultimate position; and an enzyme binding site which mimics the post-prolyl cleavage site of cytoplasmic dipeptidase.
  • CD26 i.e., DPPIV
  • DPPIV CD26
  • each D1 and D2 independently, is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH
  • X comprises an amino acid or a peptide which mimics the site of the substrate recognized by a post-prolyl cleaving enzyme.
  • the compounds in the '493 patent are inhibitors of CD26, and are also candidate inhibitors of the invention. As is discussed above, because of the low concentrations of compounds used according to the invention, it is acceptable to use, in the invention, a compound which interacts not only with the cytoplasmic enzyme, but also CD26.
  • PBMC Peripheral blood mononuclear cells
  • FIG. 2 a histogram showing that low doses of Lys-boroPro and Val-boroPro cause proliferation of PBMC of HIV-infected patients, while higher doses (10 ⁇ 4 M) do not have this effect.
  • FIGS. 3, 4 , 9 , and 10 which also present data for two control compounds OKT3, and PHA, both of which are non-specific mitogens.
  • FIG. 5 data are presented in a form which shows that low concentrations of the inhibitors of the invention have little effect on the PBMC of HIV-infected patients whose CD4 counts are lower than about 400 (the clinical indication for AIDS).
  • the natural log of the stimulation index (the vertical axis) is plotted against the natural log of the CD4 count of the patients; as shown, above a count of 400 there is particularly significant stimulation of proliferation.
  • FIG. 6 is a graph demonstrating that purified T-cells are highly sensitive to cytoplasmic T-cell dipeptidase inhibitors in moderate concentrations.
  • CD19 ⁇ B cells and CD4 ⁇ /CD8 ⁇ T-cells were isolated to high purity and incubated overnight in Val-boroPro. The amount of cell death was determined by 7AAD flow cytometry analysis. Data represent % of cell death from duplicate samples. These data are consistent with our hypothesis that the inhibitors, in moderate concentration, inhibit a cytoplasmic enzyme which ordinarily protects against apoptosis.
  • FIG. 7 presents data demonstrating that CD26 ⁇ and CD26 ⁇ PBMC are equally susceptible to T-cell cytoplasmic enzyme inhibitor-induced death, where the inhibitor is administered in moderate concentrations.
  • CD26 ⁇ and CD26 ⁇ populations were incubated overnight in the presence or absence of various concentrations of Val-boroPro. The amount of cell death was determined by 7AAD flow cytometry analysis. Data represent mean % of death from duplicate samples. These data indicate that apoptosis-inhibiting T-cell cytoplasmic enzyme is present in both CD26 ⁇ and CD26 ⁇ T-cells.
  • FIG. 8 presents data showing the effects of an inhibitor useful in the invention, Val-boroPro.
  • the experiments were carried out using two preparations: purified DPPIV (i.e., CD26), and Jurkat T-cell cytoplasmic extract, described above (Jurkat cells contain the cytoplasmic T-cell enzyme, but do not bear CD26 on their surfaces). These preparations were incubated with varying concentrations of Val-boroPro, and enzymatic activity was determined by measuring the accumulation of the fluorescent cleavage product 7-amino-4-trifluoromethylcoumarin (AFC) released from the substrate Ala-ProAFC upon enzymatic cleavage.
  • Val-boroPro inhibited both the enzyme DPPIV and the cytoplasmic T-cell enzyme in the Jurkat preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Slide Fasteners, Snap Fasteners, And Hook Fasteners (AREA)

Abstract

A method for stimulating proliferation of T-cells containing cytoplasmic post-prolyl dipeptidase activity; the method, in one aspect, involves contacting the T-cells with an organic compound at a concentration below 10−8M, wherein the compound is characterized in that: (a) it is capable of crossing the membrane of T-cells to enter the cytoplasm, (b) it binds to the dipeptidase activity at a concentration of below 10−8M, and thus (c) stimulates proliferation of the T-cells at that concentration.

Description

    RELATED APPLICATIONS
  • This application is a continuation and claims priority under 35 U.S.C. § 120 to application U.S. Ser. No. 09/491,855, filed January 26, entitled, “Potentiation of the Immune Response,” pending, which is a divisional application and claims priority under 35 U.S.C. § 120 to U.S. Ser. No. 08/852,395, filed May 7, 1997, entitled “Potentiation of the Immune Response,” now issued as U.S. Pat. No. 6,040,145, the entire contents of each of which are incorporated herein by reference.
    • STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
  • This invention was made with Government support under NIH grant No. AI36696, and the Government therefore has certain rights in this invention.
    • BACKGROUND OF THE INVENTION
  • This invention relates to treatment of viral infections using organic compounds which interact with T-cell enzymes.
  • One of the classic markers of full-blown AIDS resulting from long-term infection with HIV-1 is a severe depletion of CD4+ T-cells, which are a key component of the immune system. Attempts have been made to increase the CD4+ counts of AIDS patients, and some of these efforts, notably treatment with protease inhibitors, have met with considerable success. Other approaches, e.g., stimulation of the immune response by vaccination with viral peptides, have been less successful. The reasons for CD4+ depletion in AIDS, and resistance of CD4+ cells to stimulation by some therapies are not fully understood.
    • SUMMARY OF THE INVENTION
  • We have discovered that the activation state of human T-cells can be affected by compounds which interact with a cytoplasmic post-prolyl dipeptidase activity which has similarities to, but is distinct from, the membrane-bound T-cell serine protease CD26. The compounds useful in the invention are inhibitors of this activity, which is, in naturally-occurring T-cells in healthy individuals, involved in protection of T-cells from apoptosis, or programmed cell death. Thus, in high concentrations, the inhibitors hasten the death of T-cells, by inhibiting the protective enzyme. We have discovered, surprisingly, that at low concentrations the inhibitors exhibit a paradoxical effect: they are potent stimulators of T-cell activity in HIV-infected individuals. The concentrations of inhibitor which induce this T-cell stimulatory response at very low (on the order of 10−8-10−12M), and therefore the inhibitors can be used with minimal side effects, even if, in larger doses, the inhibitors would be toxic.
  • Our hypothesis is that the resistance to full activation observed in T-cells of HIV-infected individuals involves a blocking of the cytoplasmic enzymatic activity discussed above. We believe that this blocking of activation, involving this cytoplasmic activity, prevents differentiation of T-cells of HIV-infected individuals into effector cells, eventually leading to T-cell death.
  • Thus, the invention features a method for stimulating proliferation of T-cells of a human patient suffering from a disease state characterized by the inability of the patients' T-cells to respond normally to T-cell proliferation-inducing stimuli; the method involves contacting the T-cells with an organic compound at a concentration below 10−8M, wherein the compound is characterized in that it binds to the post-prolyl cleaving dipeptidase activity present in the cytoplasm of human T-cells, e.g., CD4+ cells or Jurkat cells.
  • Treatment according to the invention can be in vitro or in vivo. In in vivo therapy, the enzyme-interacting compound of the invention is administered such that the blood concentration in the patient (e.g., an HIV-infected patient) is below 10−11. The compounds can also be used in vitro at low concentrations to stimulate proliferation of non-infected, beneficial T-cells, such as CD4+ cells and CTL's. In this embodiment, PBMC are isolated from a patient and incubated with a concentration of lower than 10−8M of the compound, to bring about proliferation of T-cells, which are then reinfased into the patient.
  • We believe that administration of low concentrations of the inhibitors of the invention may have an allosteric effect such that the T-cell cytoplasmic enzyme, which is a multimeric (i.e., multiple subunit) enzyme, exhibits an increased affinity of the enzyme for its natural substrate or ligands, allowing the previously blocked T-cell to proceed to full activation, and hence survival, proliferation, and interleukin-2 production. Stimulation of the T-cell immune response in HIV-infected patients according to the invention yields increased numbers of immune effector cells, which can fight both HP, itself and other opportunistic pathogens.
  • Treatment according to the invention has the advantages of specificity and low toxicity, not just because of the low concentrations of inhibitor which can be used, but also because, in T-cells of patients not infected with a virus such as HIV, the inhibitors have no discernable effect. Furthermore, treatment according to the invention advantageously does not necessarily require in vitro manipulation of the T-cells from HIV-infected patients. Furthermore, no immunization is required, and treatment will be effective even where HIV proteins have mutated because the therapy targets a cellular enzyme. The fact that, in T-cells treated according to the invention in vitro, no increase in the level of the HIV protein p24 is observed, probably indicates that the T-cells which are infected with HIV are not stimulated by the low dose inhibitor treatment of the invention.
  • The invention also permits immunization of HIV-infected patients with, e.g., HIV peptides. Under normal circumstances, such patients cannot be vaccinated because of the defect in the T-cell stimulation pathway. Use of inhibitors in low doses as adjuvants can render T-cells responsive to vaccination with HIV antigens, in particular peptides.
  • Treatment of HIV-infected patients with low doses of inhibitors according to the invention can also enhance the activity of other AIDS drugs, in particular protease inhibitors. We have found that treatment according to the invention generally fails to bring about an increase in CD4− count in patients whose CD4− count is already very low, i.e., below about 400. In such patients, the CD4− count can be increased to above this level using known protease inhibitors, and the newly generated CD4− T-cells resulting from such treatment are particularly susceptible to the stimulatory effects of treatment according to the invention, leading to an optimal combination AIDS therapy. Preferably, the drugs are administered orally.
  • The low dose administration of inhibitors of the invention can also be used to produce an adjuvant effect in HIV-negative individuals, who are to be immunized with peptides or other viral antigens; this mode of vaccination can be used for prophylaxis for HIV, as well as any other viral pathogen. Ordinarily, meaningful cytolytic T-lymphocyte (“CTL”) responses, both in vitro and in vivo, have been difficult to achieve with peptide immunization. The invention should make it possible to produce significant CTL responses to viral peptides, e.g., peptides from influenza, HIV, human papilloma virus, and herpes peptides. This adjuvant effect can also be used to stimulate CTL responses to peptide antigens from other pathogens as well, e.g., pathogenic bacteria such as toxigenic E. coli, and protozoan pathogens such as the pathogens which are the causative agents of malaria and amoebic dysentery. The compounds, when used as adjuvants, are preferably administered orally.
  • The invention provides a new and highly advantageous method of potentiating the immune response in both HIV infected and uninfected patients, in methods employing extremely low concentrations of inhibitors which, at these concentrations, exhibit a paradoxical effect (i.e., they act as stimulatory rather than inhibitory molecules, as they would at higher concentrations). The very low concentrations employed according to the invention allows treatment with minimal side reactions and toxicity. The specificity of the treatment of the invention also avoids such adverse effects, which are seen, for example, in treatment with immune stimulatory compounds such as interleukin-2.
  • Other features and advantages of the invention will be apparent from the following detailed description thereof, and from the claims.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a pair of graphs showing the lymphocyte stimulatory effect of treatment of the invention on peripheral blood mononuclear cells (PBMC) from HIV-infected and uninfected patients.
  • FIG. 2 is a graph illustrating the T-cell stimulatory effects of two inhibitory compounds used according to the invention.
  • FIGS. 3, 4, and 9 are graphs showing stimulatory effects of treatment according to the invention in lymphocytes of HIV-infected patients, compared to treatment using two control compounds.
  • FIG. 5 is a graph illustrating a stimulatory effect of an inhibitor according to the invention on PBMC in vitro, showing the correlation with CD4+ counts. The data are plotted as the natural 10 g of the stimulation index (vertical dimension) versus the natural log of the CD4− count of the patient (horizontal dimension).
  • FIG. 6 is a histogram demonstrating that an inhibitor according to the invention induces dose-dependent apoptosis in resting T-cells (these dosages are higher than the extremely low doses used according to the invention).
  • FIG. 7 is a histogram demonstrating that an inhibitor according to the invention induces, at higher doses than in the invention, dose-dependent apoptosis in both CD26+ and CD26+ populations of PBMC.
  • FIG. 8 is a graph showing that an inhibitor of CD26 inhibited the cytoplasmic enzyme as well.
    • DETAILED DESCRIPTION
  • Therapeutic Compounds
  • Any organic compound can be used according to the invention which exhibits the following properties: (1) it is capable of crossing the membrane of human T-cells to reach the cytoplasm, where the compound can (2) intereact with the cytoplasmic dipeptidase present in the T-cells, in order to (3) stimulate activation/proliferation of T-cells (and most preferably CD4+ cells or CTL's) at concentrations below 10−8M.
  • A simple screening method is described below for the identification of compounds which are candidate therapeutic compounds according to the invention.
  • Substrate and Enzyme Preparation
  • The first step is to provide a cytoplasmic enzyme preparation. The preparation need not be a pure enzyme sample; a crude cytoplasmic extract is sufficient to screw compounds for the desired activity. The extract can be prepared from any human T-cell line which is negative for CD26; an example of such a suitable cell line is the commercially available Jurkat cell line.
  • A suitable enzyme-containing cell extract can be prepared as follows. First, Jurkat cells (106-1011 cells) are grown and a cell pellet is obtained by centrifugation. The cell pellet is stored in frozen condition.
  • For use in the assay, the frozen pellet is thawed by the addition of ice cold lysis buffer, in the amount of approximately 1 ml per 108 cells. The liquified material is homogenized with ten strokes of a Dounce homogenizer, and then clarified by centrifugation at 1500 g. The supernatant is removed (and saved), and the 1500 g. pellet is resuspended in lysis buffer and homogenized with ten strokes of a Dounce homogenizer. Clarification is again carried out by centrifugation at 1500 g, 4° C.
  • The 1500 g supernatants are then combined, and EDTA is added to 5 mM. The resultant liquid is centrifuged at 75,000 g at 4° C. for twenty minutes, and the supernatant is then removed and centrifuged at 175,000 g. at 4° C., for 60 minutes. The resultant supernatant, containing the cytosolic extract, is the DPPV activity-containing preparation used in the assay, described below, for candidate therapeutic compounds of the invention.
  • The assay is based on our observation that the T-cell cytoplasmic enzyme of interest is a post-prolyl cleaving serine protease. We therefore chose as a reporter substrate a compound which contains proline in the penultimate position; any of a number of substrates meeting this requirement can be used. In the assay described herein, we employed a fluorescent cleavage assay using the substrate AlaProAFC. Alternatively, a colorimetric assay can be carried out using as a substrate Gly-Pro-pNA. The choice of terminal amino acid is not critical, provided that the substrate contain a fire: terminal amino group.
  • In the assay we carried out, we employed a fluorescence spectrometer for excitation at 400 nm and emission at 505 nm. The spectrometer was calibrated for fluoresence intensity of 0.000=10 mM HEPES, pH 7.4; and fluoresence intensity of 1.000=10 Mm HEPES, 1 μM AFC.
  • To carry out the assay, between 10 and 100 μl of enzyme extact, above, is diluted to 1 ml with 10 mM HEPES, pH 7.4, containing 10 mM Ala-Pro-AFC. At least one extract/substrate sample is run without test compound, to provide a standard for comparison with the test sample.
  • In the test samples, multiple samples are run containing varying concentrations, down to 10−8M, of the test compound. The sample (with or without test compound) is placed in a cuvette, and inserted into a fluoresent spectrometer. Enzymatic activity is measured as the accumulation of fluoresence intensity (i.e., substrate cleavage product) over time (1 min.). A compound is identified as an inhibitor if the accumulative fluoresence is decreased as a result of the presence of the inhibiting compound.
  • Once a compound has been identified as an enzymatic inhibitor, as described above, further assays are carried out to determine whether the compound is capable of moving across the T-cell membrane into the cytoplasm; this is an assay which can be carried out using well-known techniques.
  • If desired, additional in vitro assays can be carried out using candidate compounds of the invention, prior to their use in vivo. One such assay employs the candidate compound at a very low concentration, in a test designed to determine whether at low concentrations the compound can stimulate the proliferation of PBMC from HIV infected patients in vitro. As is shown in the data of FIG. 4, stimulation can be measured by, e.g., incorporation of a labelled nucleotide.
  • The compounds can also be tested at higher doses to determine whether they exhibit the opposite effect of proliferation, as above, i.e., dose-dependent apoptosis caused by enzyme inhibition, as in the experiments of FIG. 6.
  • Candidate Compounds
  • As is discussed above, compounds which are potentially capable of apoptosis induction at high doses and proliferation induction at low doses are those which, at normal or high doses, inhibit cytoplasmic T-cell dipeptidase, and can cross the T-cell membrane into the T-cell cytoplasm, where the enzyme interaction occurs. The compounds thus should be organic compounds which have a free amino group at the amino terminus; a proline or proline analog at the penultimate position; and an enzyme binding site which mimics the post-prolyl cleavage site of cytoplasmic dipeptidase.
  • A number of known classes of compounds can be screened and used according to the invention. Once such class are CD26 (i.e., DPPIV) inhibitors, including those described in Bachovchin et al. U.S. Pat. No. 4,935,493, hereby incorporated by reference. In the '493 patent, there are described compounds having the structure:
    Figure US20080026007A1-20080131-C00001
    where each D1 and D2, independently, is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH; and X comprises an amino acid or a peptide which mimics the site of the substrate recognized by a post-prolyl cleaving enzyme.
  • The compounds in the '493 patent are inhibitors of CD26, and are also candidate inhibitors of the invention. As is discussed above, because of the low concentrations of compounds used according to the invention, it is acceptable to use, in the invention, a compound which interacts not only with the cytoplasmic enzyme, but also CD26.
  • The class of compounds described in the '493 patent are also discussed and exemplified in Takacs et al. U.S. patent application Ser. No. 07/923,337, corresponding to PCT Application No. WO94/03055, hereby incorporated by reference. In this application, one of the families of molecules in the '493 patent is described as the “Xaa-boroPro molecules.” exemplified by Ala-boroPro, Pro-boroPro, and Gly-boroPro. These Xaa-boroPro molecules are all candidate compounds for use in the methods of the present invention. Two of these compounds are used in some of the examples described below; those compounds are Lys-boroPro (“KPB”), and Val-boroPro (“VBP”).
    • EXAMPLE 1
  • Peripheral blood mononuclear cells (PBMC) were obtained by standard methods from HIV-infected individuals, and from uninfected individuals. Varying dosages of KBP or VBP were contacted with the PBMC in vitro, and stimulation of proliferation was measured by incorporation of 3H thymidine (cpm). The results of these experiments are shown in FIG. 1: very low doses of the Val-boroPro and Lys-boroPro stimulated proliferation of PBMC from HIV-infected patients, but not PBMC from uninfected patients.
  • As shown in FIG. 1, at no concentration of the boroPro enzyme inhibitor did it affect the PBMC from uninfected individuals. The inhibitor, at moderate concentrations, also did not cause proliferation of PBMC from HIV-infected individuals, but it did cause marked proliferation at very low concentrations (10−9 and 10−10). These results are consistent with our hypothesis, discussed above, that, at low concentrations, these enzyme inhibitors exhibit a paradoxical effect: rather than inhibiting the apoptosis-controlling cytoplasmic T-cell enzyme, they interact with that enzyme in a manner which blocks inactivation and causes proliferation of T-cells.
  • Concordant results are shown in FIG. 2, a histogram showing that low doses of Lys-boroPro and Val-boroPro cause proliferation of PBMC of HIV-infected patients, while higher doses (10−4M) do not have this effect.
  • The same results are shown in FIGS. 3, 4, 9, and 10 which also present data for two control compounds OKT3, and PHA, both of which are non-specific mitogens.
  • Referring to FIG. 5, data are presented in a form which shows that low concentrations of the inhibitors of the invention have little effect on the PBMC of HIV-infected patients whose CD4 counts are lower than about 400 (the clinical indication for AIDS). In the graph of FIG. 5, the natural log of the stimulation index (the vertical axis) is plotted against the natural log of the CD4 count of the patients; as shown, above a count of 400 there is particularly significant stimulation of proliferation.
  • FIG. 6 is a graph demonstrating that purified T-cells are highly sensitive to cytoplasmic T-cell dipeptidase inhibitors in moderate concentrations. CD19− B cells and CD4−/CD8− T-cells were isolated to high purity and incubated overnight in Val-boroPro. The amount of cell death was determined by 7AAD flow cytometry analysis. Data represent % of cell death from duplicate samples. These data are consistent with our hypothesis that the inhibitors, in moderate concentration, inhibit a cytoplasmic enzyme which ordinarily protects against apoptosis.
  • FIG. 7 presents data demonstrating that CD26− and CD26− PBMC are equally susceptible to T-cell cytoplasmic enzyme inhibitor-induced death, where the inhibitor is administered in moderate concentrations. CD26− and CD26− populations were incubated overnight in the presence or absence of various concentrations of Val-boroPro. The amount of cell death was determined by 7AAD flow cytometry analysis. Data represent mean % of death from duplicate samples. These data indicate that apoptosis-inhibiting T-cell cytoplasmic enzyme is present in both CD26− and CD26− T-cells.
  • FIG. 8 presents data showing the effects of an inhibitor useful in the invention, Val-boroPro. The experiments were carried out using two preparations: purified DPPIV (i.e., CD26), and Jurkat T-cell cytoplasmic extract, described above (Jurkat cells contain the cytoplasmic T-cell enzyme, but do not bear CD26 on their surfaces). These preparations were incubated with varying concentrations of Val-boroPro, and enzymatic activity was determined by measuring the accumulation of the fluorescent cleavage product 7-amino-4-trifluoromethylcoumarin (AFC) released from the substrate Ala-ProAFC upon enzymatic cleavage. Val-boroPro inhibited both the enzyme DPPIV and the cytoplasmic T-cell enzyme in the Jurkat preparation.
  • Other embodiments are within the following claims.

Claims (18)

1-19. (canceled)
20. A method for stimulating an antigen-specific immune response in a subject comprising
administering to an HIV-negative subject in need thereof a pathogenic peptide antigen and a compound having the structure
Figure US20080026007A1-20080131-C00002
wherein each D1 and D2, independently, is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH; and X comprises an amino acid or a peptide which mimics the site of the substrate recognized by a post-prolyl cleaving enzyme.
21. The method of claim 20, wherein the pathogenic peptide antigen is a viral peptide antigen.
22. The method of claim 21, wherein the viral peptide antigen is derived from HIV, influenza virus, human papilloma virus, and herpes virus.
23. The method of claim 20, wherein the pathogenic peptide antigen is a bacterial peptide antigen.
24. The method of claim 23, wherein the bacterial peptide antigen is derived from E. coli.
25. The method of claim 20, wherein the pathogenic peptide antigen is a protozoan peptide antigen.
26. The method of claim 25, wherein the protozoan peptide antigen is derived from a malaria causing agent or an amoebic dysentery causing agent.
27. The method of claim 20, wherein the subject has an infection other than HIV infection.
28. The method of claim 20, wherein the subject is at risk of developing an infection.
29. The method of claim 27, wherein the infection is selected from the group consisting of a bacterial infection, a viral infection or a protozoan infection.
30. The method of claim 28, wherein the infection is selected from the group consisting of a bacterial infection, a viral infection or a protozoan infection.
31. The method of claim 20, wherein the compound is administered orally.
32. The method of claim 20, wherein the compound is selected from the group consisting of Ala-boroPro, Pro-boroPro, Gly-boroPro and Lys-boroPro.
33. The method of claim 20, wherein the compound is Val-boroPro.
34. The method of claim 20, wherein the antigen-specific immune response is a cytolytic T lymphocyte response.
35. The method of claim 20, wherein X is an amino acid.
36. The method of claim 20, wherein X is a peptide.
US11/703,058 1997-05-07 2007-02-06 Potentiation of the immune response Abandoned US20080026007A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/703,058 US20080026007A1 (en) 1997-05-07 2007-02-06 Potentiation of the immune response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/852,395 US6040145A (en) 1997-05-07 1997-05-07 Potentiation of the immune response
US09/491,855 US6692753B2 (en) 1997-05-07 2000-01-26 Potentiation of the immune response
US10/778,667 US20050008644A1 (en) 1997-05-07 2004-02-13 Potentiation of the immune response
US11/703,058 US20080026007A1 (en) 1997-05-07 2007-02-06 Potentiation of the immune response

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/778,667 Continuation US20050008644A1 (en) 1997-05-07 2004-02-13 Potentiation of the immune response

Publications (1)

Publication Number Publication Date
US20080026007A1 true US20080026007A1 (en) 2008-01-31

Family

ID=25313198

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/852,395 Expired - Fee Related US6040145A (en) 1997-05-07 1997-05-07 Potentiation of the immune response
US09/491,855 Expired - Fee Related US6692753B2 (en) 1997-05-07 2000-01-26 Potentiation of the immune response
US10/778,667 Abandoned US20050008644A1 (en) 1997-05-07 2004-02-13 Potentiation of the immune response
US11/703,058 Abandoned US20080026007A1 (en) 1997-05-07 2007-02-06 Potentiation of the immune response

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/852,395 Expired - Fee Related US6040145A (en) 1997-05-07 1997-05-07 Potentiation of the immune response
US09/491,855 Expired - Fee Related US6692753B2 (en) 1997-05-07 2000-01-26 Potentiation of the immune response
US10/778,667 Abandoned US20050008644A1 (en) 1997-05-07 2004-02-13 Potentiation of the immune response

Country Status (11)

Country Link
US (4) US6040145A (en)
EP (1) EP0975359B1 (en)
JP (1) JP2002511063A (en)
AT (1) ATE250426T1 (en)
AU (1) AU724257B2 (en)
CA (1) CA2289125A1 (en)
DE (1) DE69818445T2 (en)
DK (1) DK0975359T3 (en)
ES (1) ES2207831T3 (en)
PT (1) PT975359E (en)
WO (1) WO1998050066A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
ES2285785T3 (en) 1997-09-29 2007-11-16 Point Therapeutics, Inc. STIMULATION OF IN VITRO HEMATOPOYETIC CELLS.
US6485955B1 (en) * 1997-10-06 2002-11-26 The Trustees Of Tufts University Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease
MY132924A (en) * 1998-05-04 2007-10-31 Point Therapeutics Inc Hematopoietic stimulation
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
WO2003062264A2 (en) * 2002-01-16 2003-07-31 Regents Of The University Of California Functional ligand display
AU2003248921A1 (en) * 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
PT1689757E (en) * 2003-11-12 2014-12-09 Sino Med Internat Alliance Inc Heterocyclic boronic acid compounds
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
KR101281962B1 (en) * 2006-04-11 2013-07-08 아레나 파마슈티칼스, 인크. Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AU2011237775A1 (en) 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN103539791B (en) 2010-09-22 2017-01-11 艾尼纳制药公司 Modulators of the GPR119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP6240083B2 (en) * 2011-11-22 2017-11-29 トラスティーズ オブ タフツ カレッジ Small molecule enhancer for dendritic cell carcinoma vaccine
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
BR112019020485A2 (en) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. PPARY AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4318904A (en) 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4443609A (en) 1980-05-19 1984-04-17 Petrolite Corporation Tetrahydrothiazole phosphonic acids or esters thereof
DD158109A1 (en) 1981-04-10 1982-12-29 Gunter Fischer METHOD FOR INHIBITING THE CATALYTIC ACTIVITY OF PEPTIDE HYDROLASES
US4582821A (en) 1983-11-16 1986-04-15 E. I. Du Pont De Nemours And Company Inhibition of cyclic nucleotide independent protein kinases
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4636492A (en) 1984-08-29 1987-01-13 E. I. Du Pont De Nemours And Company Inhibition of viral protease activity by peptide halomethyl ketones
US4652552A (en) 1984-09-10 1987-03-24 E. I. Du Pont De Nemours And Company Tetrapeptide methyl ketone inhibitors of viral proteases
US4644055A (en) 1984-12-17 1987-02-17 E. I. Du Pont De Nemours And Company Method for preparing specific inhibitors of virus-specified proteases
DD270382A1 (en) 1986-10-31 1989-07-26 Univ Halle Wittenberg PROCESS FOR THE COLORIMETRIC DETERMINATION OF DIPEPTIDYLPEPTIDASE IV BY DIPEPTIDE HYDRAZIDES
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
JPH04505547A (en) 1988-01-04 1992-10-01 イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー Multi-step affinity method for isolating specific cells from cell mixtures
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
JPH03504975A (en) 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション Heterofunctional cell immunizing agent, vaccine containing the same, and method for using the same
IL91307A0 (en) 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
DE3840452A1 (en) 1988-12-01 1990-06-07 Hoechst Ag (BETA) -amino-boronic acid DERIVATIVES
DE3842197A1 (en) 1988-12-15 1990-06-21 Hoechst Ag RAPID CLEANER SUBSTRATE FOR THE HIV PROTEASE
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5635386A (en) 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
DD296075A5 (en) 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De PROCESS FOR THE PREPARATION OF NEW INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
DE4033062A1 (en) 1990-10-18 1992-04-23 Merck Patent Gmbh AMINOSAEUREDERIVATE
WO1991016339A1 (en) 1990-04-14 1991-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US5378624A (en) 1990-04-23 1995-01-03 Cellpro, Incorporated Methods for removing ligands from a particle surface
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
WO1991017767A1 (en) * 1990-05-21 1991-11-28 New England Medical Center Hospitals, Inc. Method of treating inhibition of dipeptidyl aminopeptidase type iv
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
JPH06504547A (en) 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション Peptide ketoamides, keto acids and ketoesters
JPH06506463A (en) 1991-04-04 1994-07-21 ジ・アップジョン・カンパニー Compounds useful in the treatment of HIV and other retroviruses
IE922316A1 (en) 1991-07-17 1993-01-27 Smithkline Beecham Corp Retroviral protease inhibitors
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
AU2468392A (en) 1991-08-29 1993-04-05 Cytel Corporation Novel immunosuppressants
ATE349461T1 (en) * 1991-10-22 2007-01-15 New England Medical Center Inc TYPE IV DIPEPTIDYL-AMINOPEPTIDASE INHIBITORS
US6825169B1 (en) * 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
MX9206628A (en) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma PROLINABORONATE ESTER AND METHOD FOR ITS PREPARATION.
WO1993016102A1 (en) 1992-02-06 1993-08-19 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
WO1994003055A1 (en) * 1992-07-31 1994-02-17 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Producing increased numbers of hematopoietic cells by administering inhibitors of dipeptidyl peptidase iv
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
WO1994009132A1 (en) 1992-08-21 1994-04-28 Dana-Farber Cancer Institute, Inc. Human cd26 and methods for use
FR2701951B1 (en) 1993-02-24 1995-06-09 Adir NOVEL PEPTIDE DERIVATIVES OF BORONIC ACID, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU677297B2 (en) 1993-03-03 1997-04-17 Novartis Ag Peptide boronic acid derivatives having protease inhibiting activity
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
WO1994025873A1 (en) * 1993-04-23 1994-11-10 Cellpro, Incorporated Methods for enriching fetal progenitor cells from maternal blood
SE9301911D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
FR2707170A1 (en) 1993-06-04 1995-01-13 Pasteur Institut Expression of CD4 and CD26 receptors in recombinant cells, CD26 receptor inhibitors.
WO1995011689A1 (en) 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
NL9400309A (en) 1993-11-04 1995-06-01 Eurogenetics Nv Ligand which is able to bind to the adenosine deaminase binding site of CD26
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
FR2719049B1 (en) 1994-04-22 1996-06-14 Pasteur Institut Multi-representation of a peptide analog of the DPPIV substrate, in particular of the KPR type, in order to inhibit the entry of HIV into cells.
US5543396A (en) 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
DE4416963C1 (en) 1994-05-13 1995-07-13 Boehringer Ingelheim Kg Enantiomerically pure di:aryl-prolinol derivs. prodn.
EP0764151A2 (en) 1994-06-10 1997-03-26 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
FR2721611B1 (en) 1994-06-22 1996-09-27 Adir New peptide derivatives of boronic acid, their process of preparation and the pharmaceutical compositions which contain them.
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
ES2162081T3 (en) 1995-06-07 2001-12-16 Aastrom Biosciences Inc APPARATUS AND PROCEDURE FOR THE MAINTENANCE AND GROWTH OF BIOLOGICAL CELLS.
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6040145A (en) * 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV

Also Published As

Publication number Publication date
EP0975359A1 (en) 2000-02-02
EP0975359B1 (en) 2003-09-24
US20010055777A1 (en) 2001-12-27
DK0975359T3 (en) 2003-11-24
AU7274798A (en) 1998-11-27
WO1998050066A1 (en) 1998-11-12
US6040145A (en) 2000-03-21
ATE250426T1 (en) 2003-10-15
AU724257B2 (en) 2000-09-14
ES2207831T3 (en) 2004-06-01
CA2289125A1 (en) 1998-11-12
US6692753B2 (en) 2004-02-17
DE69818445T2 (en) 2004-07-22
PT975359E (en) 2004-02-27
DE69818445D1 (en) 2003-10-30
US20050008644A1 (en) 2005-01-13
JP2002511063A (en) 2002-04-09

Similar Documents

Publication Publication Date Title
US20080026007A1 (en) Potentiation of the immune response
US6100234A (en) Treatment of HIV
US11612636B2 (en) Method of treating autoimmune inflammatory crohn's disease
WO2000033654A1 (en) Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith
Grotendorst et al. Complement effects on the infectivity of Plasmodium gallinaceum to Aedes aegypti mosquitoes. I. Resistance of zygotes to the alternative pathway of complement.
US5747526A (en) Anti-HIV /Aids Chemo(C)-, immuno(I)-, or ci-therapy using tur (or related compounds) and/or NVA (or EPV)
US20050124645A1 (en) Methods and compositions for increasing CD4lymphocyte immune responsiveness
US8173598B2 (en) Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway
CN110996983A (en) Treatment to clear HIV reservoirs and reduce viral load
Haas et al. Angiotensin II-producing enzyme III from acidified serum of nephrectomized dogs
US20170073390A1 (en) Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding Assay
CA2456593A1 (en) Peptides for the diagnosis, monitoring and treatment of diabetes
Sanchez et al. Stimulation of IL-16 Release by Cells Exposed to HIV Virion Proteins
Bausback et al. Functionally important domains of C9 as defined by monoclonal antibodies to C9 inhibiting hemolysis
Spencer Characterization of γδ T cells relevant for protective tuberculosis immunity: T cell specificity, antigen identification and mechanisms of inhibition
Warburg Sporogonic cycle of a malaria parasite

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION